Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia.
Cartwright
M S
MS
Wake Forest University School of Medicine, Department of Neurology, Winston-Salem, NC 27157, USA. mcartwri@wfubmc.edu
Jeffery
D R
DR
Lewis
Z T
ZT
Koty
P P
PP
Stewart
W T
WT
Molnár
I
I
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D043025:Oligoclonal Bands / Q000134:cerebrospinal fluid; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology*; D012074:Remission Induction; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007370:Interferon Type I; D043025:Oligoclonal Bands; D008942:Mitoxantrone